ImmuPharma (LON:IMM) Stock Price Up 5.3% – Still a Buy?

ImmuPharma plc (LON:IMMGet Free Report) shares shot up 5.3% during mid-day trading on Friday . The stock traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.69 ($0.05). 100,501,945 shares changed hands during trading, an increase of 231% from the average session volume of 30,396,029 shares. The stock had previously closed at GBX 3.50 ($0.04).

ImmuPharma Price Performance

The firm’s 50-day moving average price is GBX 1.44 and its 200-day moving average price is GBX 1.65. The company has a market cap of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

See Also

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.